Expression and activity of taxane-metobolizing enzymes in ovarian tumors

Gynecologic Oncology

Volumn 108, Issue 2, 2008, Pages 355-360

  DeLoia, Julie A ^a   Zamboni, William C ^b,c   Jones, Jacqueline M ^a   Strychor, Sandra ^b,c   Kelley, Joseph L ^a   Gallion, Holly H ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Cytochrome P450; Ovarian cancer; Pharmacogenetics

Indexed keywords

ABC TRANSPORTER; CYTOCHROME P450; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DOCETAXEL; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; TAXANE DERIVATIVE;

ARTICLE; CANCER CELL; CELL GROWTH; CELL TRANSPORT; CLINICAL FEATURE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENE EXPRESSION; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; TAXOIDS; TUMOR CELLS, CULTURED;

EID: 38649115996     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.10.029     Document Type: Article

References (27)

1. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334 (1996) 1-6
2. Piccart M.J., Bertelsen K., James K., Cassidy J., Mangioni C., Simonsen E., et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92 (2000) 699-708
3. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al. Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21 (2003) 3194-3200
4. van Zuylen L., Sparreboom A., van der Gaast A., Nooter K., Eskens F.A., Brouwer E., et al. Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933. Eur J Cancer 38 (2002) 1090-1099
5. Chan H.S., Haddad G., Thorner P.S., DeBoer G., Lin Y.P., Ondrusek N., et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Eng J Med 325 (1991) 1608-1614
6. Chan H.S., Grogan T.M., Haddad G., DeBoer G., and Ling V. P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. J Natl Cancer Inst 89 (1997) 1706-1715
7. Fellay J., Marzolini C., Meaden E.R., Back D.J., Buclin T., Chave J.P., et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359 (2002) 30-36
8. Guengerich F.P. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39 (1999) 1-17
9. Goh B., Lee S., Wang L.Z., Fan L., Guo J.Y., Lamba J., et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 20 (2002) 3683-3690
10. Klose T.S., Blaisdell J.A., and Goldstein J.A. Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J Biochem Mol Toxicol 13 (1999) 289-295
11. Martinez C., Garcia-Martin E., Pizarro R.M., Garcia-Gamito F.J., and Agundez J.A. Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy. Br J Cancer 87 (2002) 681-686
12. Miyoshi Y., Ando A., Takamura Y., Taguchi T., Tamaki Y., and Noguchi S. Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues. Int J Cancer 97 (2002) 129-132
13. Fujitaka K., Oguri T., Isobe T., Fujiwara Y., and Kohno N. Induction of cytochrome P450 3A4 by docetaxel in peripheral monocuclear cells and its expression in lung cancer. Cancer Chemother Pharmacol 48 (2001) 42-46
14. Knupfer H., Schmidt R., Stanitz D., Brauckhoff M., Schonfelder M., and Preiss R. CYP2C and IL-6 expression in breast cancer. Breast 13 (2004) 28-34
15. Koch I., Weil R., Wolbold R., Brockmöller J., Hustert E., Burk O., et al. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 30 (2002) 1108-1114
16. Westlind-Johnsson A., Malmebo S., Johansson A., Otter C., Andersson T.B., Johansson I., et al. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 31 (2003) 755-761
17. Collins C., Rommens J.M., Kowbel D., Godfrey T., Tanner M., Hwang S.I., et al. Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. Proc Natl Acad Sci U S A 95 (1998) 8703-8708
18. Parise R.A., Ramanathan R.R., Zamboni W.C., and Egorin M.J. Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma. J Chromatogr Analyt Technol Biomed Life Sci 783 (2003) 231-236
19. Rowland M., and Tozer T. Clinical Pharmacokinetics: Concepts and Applications. 2nd ed. Philadephia, PA.: Lippincott, Williams & Wilkins, US (1989)
20. Modugno F., Knoll C., Kanbour-Shakir A., and Romkes M.A. A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat 82 (2003) 191-197
21. Martinez-Jimenez C.P., Jover R., Donato M.T., Castell J.V., and Gomez-Lechon M.J. Transcriptional regulation and expression of CYP3A4 in hepatocytes. Curr Drug Metab 8 (2007) 185-194
22. Ozalp S.S., Yalcin O.T., Tanir M., Kabukcuoglu S., and Etiz E. Multidrug resistance gene-1 (Pgp) expression in epithelial ovarian cancer malignancies. Eur J Gynaecol Oncol 23 (2002) 337-340
23. Ikeda K., Sakai K., Yamamoto R., Hareyama H., Tsumura N., Watari H., et al. Multivariate analysis for prognostic significance of histologic subtype, GST-pi, ABCB1, and p53 in stages II-IV ovarian cancer. Int J Gynecol Cancer 13 (2003) 776-784
24. Kamazawa S., Kigawa J., Kanamori Y., Itamochi H., Sato S., Iba T., et al. Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol Oncol 86 (2002) 171-176
25. Lehmann J.M., McKee D.D., Watson M.A., Wilson T.M., Moore J.T., and Kliewer S.A. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102 (1998) 1016-1023
26. Synold T.W., Dussault I., and Forman B.M. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 7 (2001) 584-590
27. Gerbal-Chaloin S., Pascussi J.M., Pichard-Garcia L., Daujat M., Waechter F., Fabre J.M., et al. Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos 29 (2001) 242-251